81
Participants
Start Date
February 29, 2008
Primary Completion Date
June 30, 2009
Study Completion Date
December 31, 2009
Botulinum toxin type A
Single injection cycle, intradetrusor injection at baseline visit 2 of either 125 units (arm A), 250 units (arm B) or 500 units (arm C) in total.
Placebo
Single injection cycle, intradetrusor injection at baseline (visit 2).
Struttura Complessa di Neuro-Urologia, Torino
UZ Gasthuisberg, Leuven
Unità Spinale, Ospedale Niguarda, Milan
Hospital San Rafael, Madrid
Hôpital Rangueil - CHU de Toulouse, Toulouse
Hôpital Michallon - CHU de Grenoble, Grenoble
Hospital Clínico Universitario Canarias, San Cristóbal de La Laguna
Hospital Universitario La Fe, Valencia
Unità Spinale, Azienda Ospedaliera Careggi, Florence
Medizinische Einrichtungen der RWTH, Aachen
Praxis für Urologie, Bad Kreuznach
Städtisches Klinikum Neunkirchen gGmbH, Neunkirchen
Hôpital Henri Gabrielle - Hôpitaux Civils de Lyon, Saint-Genis-Laval
Krankenhaus St. Trudpert, Pforzheim
Groupe Hospitalier Pitié-Salpétrière, Paris
Hôpital Charles Nicolle - CHU de Rouen, Rouen
Praxis für Urologie, Lahr
Praxis für Urologie, Emmendingen
Beckenboden Zentrum München, München
Praxis für Urologie, Günzburg
ULB Hôpital Erasme, Brussels
CH Régional Huy - Polyclinique A Rue Trois Ponts, Huy
CHU Liege Sart Tilman, Liège
Urologická klinika, Olomouc
Urologické oddělení, Prague
General Urology Academisch Ziekenhuis Maastricht, Maastricht
VU Medisch Centrum Amsterdam, Amsterdam
UMC St. Radboud, Nijmegen
Erasmus MC, Universitair Medisch Centrum Rotterdam, Rotterdam
Southmead Hospital, Bristol
Western General Hospital, Edinburgh
St George's Hospital, London
Churchill Hospital, Oxford
Royal Berkshire Hospital, Reading
Lead Sponsor
Ipsen
INDUSTRY